Overall, and in contrast to rs2036527, the ‘T’ allele of rs588765 was associated with short term smoking abstinence (only during treatment) in participants who received either active pharmacotherapy or placebo, with a differing direction of effect for active versus placebo treatment (see Fig.3C for statistical comparisons). Among the participants who received the active nicotine gum treatment (Study 1), those with the ‘T’ allele of rs588765 had higher abstinence rates during treatment (OR=2.31, Fig.1A&3A). Adjusting for age, sex, baseline CPD, menthol status and type of counseling sessions did not alter the association between rs588765 and smoking abstinence (OR=2.39, Fig.3A) nor did adjusting for CYP2A6 genotype (OR=2.34). In the second study, while the directions of effect were similar to nicotine gum, the magnitude was smaller and we did not observe any significant association between rs588765 and smoking abstinence in those receiving active bupropion or placebo treatment (Fig.1B&3B).
